There are currently 1258 clinical trials in Miami, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Miami, GSK Investigational Site, University of Miami Miller School of Medicine-Sylvester Cancer Center and University of Miami Miller School of Medicine. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
NCT01526681
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
ALL
Ages:
All
Trial Updated:
07/25/2024
Locations: RANGER: University of Miami, Miami, Florida
Conditions: Peripheral Nerve Injuries
Register for Updates
Integrated Navigation Services for Treatment Adherence, Counseling, and Research
NCT04663152
Recruiting
The goal of this research is to determine whether a Community Health Worker (CHW) intervention including a mobile telehealth (M-Health) component can help achieve long term viral suppression among Black people with poorly controlled HIV.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: University of Miami, Miami, Florida
Conditions: HIV Infection Primary
Register for Updates
Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV
NCT02323399
Recruiting
The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population, ≥12 to 16 year old patients undergoing general and neuraxial anesthesia. The secondary objectives are to describe changes in blood pressure and heart rate, time to onset and to maximal response, and the duration of response; to assess the safety of the product in this population; and to character... Read More
Gender:
ALL
Ages:
Between 12 years and 16 years
Trial Updated:
07/22/2024
Locations: Jackson Memorial Hospital, Miami, Florida
Conditions: Hypotension
Register for Updates
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT05826964
Recruiting
The majority of patients (pts) with breast cancer have hormone receptor positive (HR+) disease, and this holds true for pts with advanced breast cancer (ABC). Currently frontline therapy for pts with HR+ ABC is antihormonal therapy with an aromatase inhibitor or selective estrogen receptor degrader plus a CDK4/6i. The proposed trial is a randomized study to further evaluate the potential benefit of switching a frontline regimen at the time that a molecular signal, ctDNA, suggests progression pri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2024
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Register for Updates
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
NCT00920972
Recruiting
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/19/2024
Locations: University of Miami, Miami, Florida +1 locations
Conditions: Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Register for Updates
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
NCT05924477
Recruiting
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2024
Locations: Bascom Palmer Eye Institute, Miami, Florida
Conditions: Glaucoma
Register for Updates
Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
NCT06496217
Recruiting
Evaluate the Safety and Pharmacokinetics of MBX 2109 in Adult Subjects with Normal and Impaired Renal Function
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/17/2024
Locations: MBX Biosciences Investigational Site, Miami, Florida
Conditions: Renal Impairment
Register for Updates
RESET System Pivotal Trial (Rev F)
NCT04101669
Recruiting
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the RESET System plus moderate intensity lifestyle and dietary counseling compliant with 2024 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle an... Read More
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
07/16/2024
Locations: University of Miami Hospital, Miami, Florida
Conditions: Diabetes type2, Obesity
Register for Updates
Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities
NCT06062342
Recruiting
The purpose of this study is to assess the effectiveness of the FPI bundled implementation strategy in increasing HIV testing, Pre-exposure prophylaxis (PrEP) linkage (e.g., prescription) and knowledge, and condom use/access.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2024
Locations: University of Miami, Miami, Florida
Conditions: Hiv
Register for Updates
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
NCT06392295
Recruiting
The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy; 2. Preserving quality of life after radiation therapy; 3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: University of Miami, Miami, Florida
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer
Register for Updates
Individualized Treatments in Adults With Relapsed/Refractory Cancers
NCT06024603
Recruiting
A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2024
Locations: Florida International University, Miami, Florida
Conditions: Refractory Cancer, Relapsed Cancer
Register for Updates
Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML
NCT04365179
Recruiting
This is an open-label Phase 1b study of NEROFE following a traditional 3+3 design to assess safety and to determine the Recommended Phase 2 Dose (RP2D) of NEROFE in patients with MDS or AML. IV NEROFE will be administered three times per week on alternate days. The exact dosage will be determined using the body surface area (BSA) measured on Day 1 of each cycle.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2024
Locations: University of Miami Hospital and Clinics / Sylvester Comprehensive Cancer Center, Miami, Florida
Conditions: Advanced MDS, AML
Register for Updates